Evidence map›Paper›PMID 41392882›Full record

SynthesisInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026

Adverse outcomes among pregnant women with COVID-19 according to hospitalization status: A prospective individual participant data meta-analysis in Europe and North America.

Odette de Bruin, Emeline Maisonneuve, Eimir Hurley, Hedvig M E Nordeng, Anick Bérard, Odile Sheehy, Padma Kaul, Mayura U Shinde, Austin Cosgrove, Jennifer G Lyons and 25 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Adverse outcomes among pregnant women with COVID-19 according to hospitalization status: A prospective individual participant data meta-analysis in Europe and North America.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Odette de BruinDepartment of Data Science & Biostatistics, Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.ORCID https://orcid.org/0000-0001-6295-3411
Emeline MaisonneuveInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Eimir HurleyPharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University Oslo (UiO), Oslo, Norway.
Hedvig M E NordengPharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University Oslo (UiO), Oslo, Norway.
Anick BérardFaculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
Odile SheehyFaculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
Padma KaulDepartment of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Mayura U ShindeDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Austin CosgroveDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Jennifer G LyonsDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Elizabeth Messenger-JonesDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Maria E KempnerDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Sengwee TohDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Wei HuaOffice of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
José J Hernández-MuñozOffice of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Leyla SahinOffice of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Carolyn E CestaDepartment of Medicine Solna, Center for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.
David HäggDepartment of Medicine Solna, Center for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden.
Rosa GiniEpidemiology Unit, Tuscan Regional Healthcare Agency, Florence, Italy.
Olga PaolettiEpidemiology Unit, Tuscan Regional Healthcare Agency, Florence, Italy.
Beatriz Poblador-PlouEpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, Miguel Servet University Hospital, Zaragoza, Spain.
Sue JordanFaculty of Medicine, Health and Life Science, Swansea University, Swansea, UK.
Clara L Rodríguez-BernalNetwork for Research on Chronicity, Primary Care and Health Promotion (RICAPPS), Research Network on Health Services in Chronic Diseases, Institute of Health Carlos III, Madrid, Spain.
Francisco Sánchez-SáezNetwork for Research on Chronicity, Primary Care and Health Promotion (RICAPPS), Research Network on Health Services in Chronic Diseases, Institute of Health Carlos III, Madrid, Spain.
Régis LassalleBordeaux PharmacoEpi, INSERM CIC-P1401, Université de Bordeaux, Bordeaux, France.
Marie-Agnès BernardBordeaux PharmacoEpi, INSERM CIC-P1401, Université de Bordeaux, Bordeaux, France.
Fariba AhmadizarDepartment of Data Science & Biostatistics, Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
Guillaume FavreMaterno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital, Lausanne, Switzerland.
Alice PanchaudInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Kitty W M BloemenkampDivision Woman and Baby, Department of Obstetrics, Wilhelmina Children's Hospital, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
Kelly PlueschkeEuropean Medicines Agency, Amsterdam, The Netherlands.
Corinne de VriesEuropean Medicines Agency, Amsterdam, The Netherlands.
Satu J SiiskonenDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
Miriam C J M SturkenboomDepartment of Data Science & Biostatistics, Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.
CONSIGN Collaboration Group

Funding

Canada Foundation for InnovationCIHREuropean Medicines AgencyFDA HHS
6 · The paper itself

Abstract

backgroundUnderstanding the varied impact of COVID-19 severity on pregnancy outcomes is crucial for informed clinical management and targeted interventions.

objectiveTo evaluate the impact of COVID-19 on pregnancy outcomes, distinguishing between pregnant women managed in primary care and those requiring hospitalization. SEARCH STRATEGY: Regulatory authorities actively promoted global cooperation on COVID-19's impact during pregnancy. Data were obtained through these regulatory bodies and direct researcher communication rather than through systematic searches. SELECTION CRITERIA: Data sources required secondary population-based data to identify pregnancies with COVID-19, along with hospitalization, diagnostic and medication codes. Eligibility for the meta-analysis was determined through protocol evaluation and researcher consultations. DATA COLLECTION AND ANALYSIS: PRISMA-IPD and Cochrane guidelines for prospective meta-analysis were followed. Protocols and definitions were standardized across sources, and a common R script was developed. Initially, crude and adjusted relative risks (aRR) with 95% confidence intervals (CI) were calculated to assess adverse outcomes in pregnant women with and without COVID-19 in each data source. Estimates were stratified by trimester at infection and hospitalization status. Subsequently, data were pooled using a random-effects meta-analysis. MAIN

resultsData from 10 sources across seven countries contributed to the meta-analysis, including 86 210 pregnant women diagnosed with COVID-19, of whom 4.4% were hospitalized. Non-hospitalized pregnant women with COVID-19 had no increased risks of adverse outcomes compared to pregnant women without COVID-19. However, hospitalized women with COVID-19 in each trimester had higher risks of cesarean section, preterm birth, and LBW compared to pregnant women without COVID-19. Hospitalization due to COVID-19 in the third trimester was associated with increased risk of stillbirth (aRR 5.90, 95% CI: 2.22-15.71, I CONCLUSIONS AND RELEVANCE: COVID-19 requiring hospitalization is associated with adverse pregnancy outcomes, emphasizing the need to prevent severe illness during pregnancy. This study also highlights the importance of international collaboration for gathering pregnancy data and shows that building global research networks is essential for responding to future health crises.

Indexed as

COVID-19HospitalizationPregnancy Complications, InfectiousPregnancy OutcomeAdultEuropeFemaleHumansInfant, NewbornNorth AmericaPregnancyProspective StudiesSARS-CoV-2adverse outcomesCOVID‐19hospitalizationinternational collaborationmeta‐analysispregnancy

Identifiers

PMID41392882
PMCPMC13173624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.